DVS Controlled Pilot
Agreed scope, baseline, guided execution, success measures and a documented scale decision.
View pilot scope →Connect URS, risk, IQ/OQ/PQ, test results, approvals and the RTM in one controlled workflow.
PHARPRO DVS combines 30 validation document builders, built-in drafting intelligence, requirements traceability and controlled electronic-signature workflows. Web-based access; published plans start at $253/month. Validate the configured platform for your intended use.
A real conversation with a validation practitioner
Tell Mohammad what your team validates today. You will get a direct view on whether DVS is relevant, what to test next and whether a detailed demo is worth your time.
Use this qualified path when your team is ready to review a representative workflow, lifecycle coverage, traceability, signatures and supplier evidence in a 30-minute session.
Replace disconnected Word and Excel validation records with one controlled workflow for URS, risk assessment, IQ/OQ/PQ, RTM, review, approval and audit trails.
Drafting assistance helps structure first drafts for URS, risk assessments, IQ/OQ/PQ protocols and other records. Qualified users remain responsible for review and suitability.
Purpose-built templates for every stage: Validation Master Plan, URS, Risk Assessment, IQ/OQ/PQ, Test Scripts, Discrepancy Log, RTM, and VSR.
Automated RTM links user requirements to test cases and test results - providing full traceability from URS to final report.
Controlled electronic-signature workflows with role-based access, signature meaning, date, time and user attribution—designed to support a Part 11 assessment.
Generate controlled PDFs with formatting, signatures, version history and document-control headers, ready for the regulated company’s review and approval process.
Configurable review and approval workflows ensure documents go through the right hands in the right order, with automated notifications and status tracking.
Thirty pre-structured builders spanning common validation lifecycle records, ready for controlled drafting and review.
Start with the workflow, intended use and evidence your quality team needs before deciding how to proceed.
Discuss your current validation workflow with a practitioner and decide whether a detailed evaluation is useful. No generic deck and no purchase commitment.
Agree intended use, workspace configuration, roles, supplier evidence, qualification approach and implementation responsibilities.
Test drafting intelligence, traceability, approvals, audit-trail records and exports against defined acceptance criteria before controlled rollout.
Transparent pricing. No hidden fees. Cancel anytime. All plans include access to the full document library.
Up to 10 concurrent users. Best for small validation teams.
Up to 25 concurrent users. Best for mid-size quality teams.
Unlimited users. For large organisations and multi-site deployments.
From validation planning to controlled output, DVS is designed to support contributors, reviewers and approvers—not only the document author.
Review and approve validation documents without chasing paper. Configurable approval workflows keep every signature on track and fully auditable.
Use built-in drafting assistance for IQ/OQ/PQ protocols and connect requirements to test cases through the RTM. Qualified users retain review responsibility.
Execute test scripts digitally with controlled electronic-signature workflows and audit-trail records designed to support a Part 11 assessment.
Export controlled PDFs with version history, electronic signatures and document-control headers for internal review, approval and applicable submission workflows.
Web-based access with no local installation. Controlled use begins after agreed configuration, onboarding, qualification and approval activities.
Manage multiple client projects in one platform. Separate workspaces, shared document libraries, and branded exports - all in a single subscription.
Compare both approaches against intended use, traceability, record controls, review effort and total validated cost.
| Feature | PHARPRO DVS | Word / Excel / Paper |
|---|---|---|
| IQ/OQ/PQ first draft | Built-in first-draft assistance | Manual template drafting |
| Requirements Traceability Matrix | Connected and system-generated | Requires manual controls |
| FDA 21 CFR Part 11 e-signatures | Built-in controlled workflow | Requires a separate controlled solution |
| Audit trail | System-generated audit trail | Manual or absent |
| Controlled PDF export | System-generated | Template and governance dependent |
| Time to deploy | Scope dependent | Existing controls determine effort |
Bring one representative workflow or document set. We will show the relevant lifecycle, traceability and approval controls.
Or message us on WhatsAppDemonstrate one requirement from URS through risk, test case, execution result and final RTM. Confirm how changes and exceptions remain traceable.
Ask for a controlled change, signature and audit-trail demonstration. Record what the platform controls and which procedures remain your responsibility.
Review supplier information, architecture, security, change notification, release evidence, backup, export and validation-support responsibilities.
In-depth guides from Mohammad Awawdeh on validation software, FDA compliance, and documentation best practice.
Start with a free 10-minute fit check, or request a detailed workflow demo when your evaluation team is ready.
Why PHARPRO
PHARPRO aligns each engagement with the regulations and guidance applicable to the client’s product, market and quality system. Final responsibility and approval remain with the regulated company.
Practical guides for pharmaceutical teams moving from disconnected documents to controlled digital validation workflows.
Choose the commercial pilot to test one representative lifecycle, or review the Trust Center before technical and supplier due diligence.
Agreed scope, baseline, guided execution, success measures and a documented scale decision.
View pilot scope →Intended use, human accountability, access, traceability, validation responsibility and evidence status.
Review trust framework →